Novartis registers two Phase I trials: TRB191 in SCLC and XEP527 in schizophreniaNov 6Weekly roundup, 10 itemsArdtartemether and lumefantrine
Novartis registers Phase 3 urticaria, pruritus trials; posts malaria and leishmaniasis dataSep 11Weekly roundup, 5 itemscipargaminINE963